• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis.

作者信息

Powers Camille M, Yang Andrew K, Verma Hannah, Orloff Jeremy, Piontkowski Austin J, Gulati Nicholas

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

出版信息

JMIR Dermatol. 2024 May 2;7:e53792. doi: 10.2196/53792.

DOI:10.2196/53792
PMID:38696235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11099803/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b79a/11099803/5f471f8475ba/derma_v7i1e53792_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b79a/11099803/5f471f8475ba/derma_v7i1e53792_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b79a/11099803/5f471f8475ba/derma_v7i1e53792_fig1.jpg

相似文献

1
Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis.在线患者对纳武利尤单抗和帕博利珠单抗所致皮肤免疫相关不良事件的态度：情感分析
JMIR Dermatol. 2024 May 2;7:e53792. doi: 10.2196/53792.
2
Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.抗 PD-1 治疗的皮肤不良反应——系统评价。
J Am Acad Dermatol. 2020 Nov;83(5):1415-1424. doi: 10.1016/j.jaad.2020.04.058. Epub 2020 Apr 19.
3
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.与程序性细胞死亡蛋白1抑制剂治疗相关的皮肤不良反应的发作时间。
JAMA Dermatol. 2018 Sep 1;154(9):1057-1061. doi: 10.1001/jamadermatol.2018.1912.
4
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.免疫检查点抑制剂在癌症中的比较安全性：系统评价和网络荟萃分析。
BMJ. 2018 Nov 8;363:k4226. doi: 10.1136/bmj.k4226.
5
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.培戈利单抗联合帕博利珠单抗或纳武利尤单抗治疗晚期实体瘤患者（IVY）：一项多中心、多队列、开放标签、Ib 期研究。
Lancet Oncol. 2019 Nov;20(11):1544-1555. doi: 10.1016/S1470-2045(19)30514-5. Epub 2019 Sep 25.
6
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.接受纳武利尤单抗或帕博利珠单抗治疗的癌症患者的内分泌毒性：一项大型多中心研究的结果。
J Endocrinol Invest. 2020 Mar;43(3):337-345. doi: 10.1007/s40618-019-01112-8. Epub 2019 Sep 21.
7
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.患者肝癌对纳武利尤单抗发生超敏反应后，使用帕博利珠单抗治疗。
Am J Health Syst Pharm. 2019 Oct 15;76(21):1749-1752. doi: 10.1093/ajhp/zxz189.
8
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.免疫检查点抑制剂相关的类肉瘤样肉芽肿性炎症：在接受晚期恶性黑色素瘤治疗的患者的淋巴结细针抽吸细胞学中检测到的一种罕见不良事件。
Hum Pathol. 2019 Sep;91:69-76. doi: 10.1016/j.humpath.2019.07.001. Epub 2019 Jul 4.
9
Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology.皮肤肿瘤学中与免疫检查点抑制剂相关的心脏毒性。
J Am Acad Dermatol. 2020 Apr;82(4):986-994. doi: 10.1016/j.jaad.2019.08.033. Epub 2019 Aug 19.
10
Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.在与免疫检查点抑制剂相关的甲状腺功能障碍患者中，抗甲状腺抗体阳性率较低。
J Endocrinol Invest. 2019 Dec;42(12):1443-1450. doi: 10.1007/s40618-019-01058-x. Epub 2019 May 15.

本文引用的文献

1
Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.免疫检查点抑制剂治疗的皮肤不良反应与癌症生存预后：系统评价和荟萃分析。
JAMA Dermatol. 2023 Oct 1;159(10):1093-1101. doi: 10.1001/jamadermatol.2023.3003.
2
Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.医师对免疫检查点抑制剂相关免疫相关不良事件的认知。
J Natl Compr Canc Netw. 2022 Dec;20(12):1316-1320. doi: 10.6004/jnccn.2022.7064.
3
Health Natural Language Processing: Methodology Development and Applications.
健康自然语言处理：方法学发展与应用
JMIR Med Inform. 2021 Oct 21;9(10):e23898. doi: 10.2196/23898.
4
Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.CheckMate 057 研究中纳武利尤单抗或多西他赛治疗晚期非鳞状非小细胞肺癌患者的健康相关生活质量和症状评估。
Eur J Cancer. 2018 Oct;102:23-30. doi: 10.1016/j.ejca.2018.05.005. Epub 2018 Aug 10.
5
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.帕博利珠单抗对比化疗用于晚期 PD-L1 阳性 NSCLC 的疗效及安全性（KEYNOTE-024）：一项多中心、国际、随机、开放标签的 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1600-1609. doi: 10.1016/S1470-2045(17)30690-3. Epub 2017 Nov 9.
6
Exploring the factors that influence medication rating Web sites value to older adults: A cross-sectional study.探索影响药物评价网站对老年人价值的因素：一项横断面研究。
Geriatr Nurs. 2016 Jan-Feb;37(1):36-43. doi: 10.1016/j.gerinurse.2015.10.011. Epub 2015 Nov 10.
7
Use of sentiment analysis for capturing patient experience from free-text comments posted online.使用情感分析从在线发布的自由文本评论中获取患者体验。
J Med Internet Res. 2013 Nov 1;15(11):e239. doi: 10.2196/jmir.2721.